These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Outcomes of Eyes Lost to Follow-up with Proliferative Diabetic Retinopathy That Received Panretinal Photocoagulation versus Intravitreal Anti-Vascular Endothelial Growth Factor. Obeid A; Su D; Patel SN; Uhr JH; Borkar D; Gao X; Fineman MS; Regillo CD; Maguire JI; Garg SJ; Hsu J Ophthalmology; 2019 Mar; 126(3):407-413. PubMed ID: 30077614 [TBL] [Abstract][Full Text] [Related]
9. Recent clinically relevant highlights from the Diabetic Retinopathy Clinical Research Network. Krick TW; Bressler NM Curr Opin Ophthalmol; 2018 May; 29(3):199-205. PubMed ID: 29528861 [TBL] [Abstract][Full Text] [Related]
10. Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial. Bressler SB; Qin H; Melia M; Bressler NM; Beck RW; Chan CK; Grover S; Miller DG; JAMA Ophthalmol; 2013 Aug; 131(8):1033-40. PubMed ID: 23807371 [TBL] [Abstract][Full Text] [Related]
11. Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy. Ip MS; Domalpally A; Sun JK; Ehrlich JS Ophthalmology; 2015 Feb; 122(2):367-74. PubMed ID: 25439595 [TBL] [Abstract][Full Text] [Related]
12. Anti-Vascular Endothelial Growth Factor and Panretinal Photocoagulation Use after Protocol S for Proliferative Diabetic Retinopathy. Azad AD; Chen EM; Hinkle J; Rayess N; Wu D; Eliott D; Mruthyunjaya P; Parikh R Ophthalmol Retina; 2021 Feb; 5(2):151-159. PubMed ID: 32693033 [TBL] [Abstract][Full Text] [Related]
13. Rationale and Application of the Protocol S Anti-Vascular Endothelial Growth Factor Algorithm for Proliferative Diabetic Retinopathy. Sun JK; Glassman AR; Beaulieu WT; Stockdale CR; Bressler NM; Flaxel C; Gross JG; Shami M; Jampol LM; Ophthalmology; 2019 Jan; 126(1):87-95. PubMed ID: 30096354 [TBL] [Abstract][Full Text] [Related]
14. Retinal function in eyes with proliferative diabetic retinopathy treated with intravitreal ranibizumab and multispot laser panretinal photocoagulation. Messias K; Barroso RM; Jorge R; Messias A Doc Ophthalmol; 2018 Oct; 137(2):121-129. PubMed ID: 30209775 [TBL] [Abstract][Full Text] [Related]
15. Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab. Bressler SB; Liu D; Glassman AR; Blodi BA; Castellarin AA; Jampol LM; Kaufman PL; Melia M; Singh H; Wells JA; JAMA Ophthalmol; 2017 Jun; 135(6):558-568. PubMed ID: 28448655 [TBL] [Abstract][Full Text] [Related]
16. Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy. Diabetic Retinopathy Clinical Research Network* JAMA Ophthalmol; 2013 Mar; 131(3):283-93. PubMed ID: 23370902 [TBL] [Abstract][Full Text] [Related]
17. Panretinal Photocoagulation Versus Ranibizumab for Proliferative Diabetic Retinopathy: Patient-Centered Outcomes From a Randomized Clinical Trial. Beaulieu WT; Bressler NM; Melia M; Owsley C; Mein CE; Gross JG; Jampol LM; Glassman AR; Am J Ophthalmol; 2016 Oct; 170():206-213. PubMed ID: 27523491 [TBL] [Abstract][Full Text] [Related]
18. Contrast sensitivity evaluation in high risk proliferative diabetic retinopathy treated with panretinal photocoagulation associated or not with intravitreal bevacizumab injections: a randomised clinical trial. Preti RC; Ramirez LM; Monteiro ML; Carra MK; Pelayes DE; Takahashi WY Br J Ophthalmol; 2013 Jul; 97(7):885-9. PubMed ID: 23686001 [TBL] [Abstract][Full Text] [Related]